23-May-2018
Removal from Official List
20-Apr-2018
Appendix 4C - Quarter Ended 31 March 2018
27-Mar-2018
Initial Director's Interest Notice
23-Mar-2018
Director Appointment
26-Feb-2018
Half Yearly Report and Accounts - 31 December 2017
18-Jan-2018
Appendix 4C - Quarter Ended 31 December 2017
20-Nov-2017
Results of Meeting
20-Nov-2017
Chairman's Address to Shareholders
18-Oct-2017
Notice of Annual General Meeting/Proxy Form
17-Oct-2017
Appendix 4C - Quarter Ended 30 September 2017
28-Sep-2017
Appendix 4G - Corporate Governance
28-Sep-2017
Annual Report to shareholders
30-Aug-2017
Preliminary Final Report
31-Jul-2017
Appendix 4C - Quarter Ended 30 June 2017
11-Apr-2017
Appendix 4C - Quarter Ended 31 March 2017
22-Feb-2017
Half Yearly Report and Accounts - 31 December 2016
17-Jan-2017
Appendix 4C - Quarter Ended 31 December 2016
19-Dec-2016
Auditor Appointment / Resignation
29-Nov-2016
Results of Meeting
29-Nov-2016
Chairman's Address to Shareholders
25-Oct-2016
Notice of Annual General Meeting/Proxy Form
19-Oct-2016
Appendix 4C - Quarter Ended 30 September 2016
14-Oct-2016
Initial Director's Interest Notice- J Rainbow
14-Oct-2016
Initial Director's Interest Notice- T Heesh
14-Oct-2016
Final Director's Interest Notice- B Hancox
14-Oct-2016
Final Director's Interest Notice- R Treagus
11-Oct-2016
Change in Board Composition
22-Aug-2016
Change of Registered Office & Company Secretary
18-Aug-2016
Appendix 4G - Corporate Governance Statement
18-Aug-2016
Preliminary Final Report - 30 June 2016
5-Aug-2016
Appendix 4C - Quarter Ended 30 June 2016
27-May-2016
Response to ASX Query
26-May-2016
Change of Director's Interest Notice - Bruce Hancox
19-May-2016
Results of 2015 Annual General Meeting
19-May-2016
Chairman's Address to Shareholders
10-May-2016
Appendix 4C - Quarter Ended 31 March 2016
15-Apr-2016
Notice of 2015 Annual General Meeting/Proxy Form
11-Mar-2016
Half Yearly Report and Accounts - 31 December 2015
9-Feb-2016
Appendix 4C - Quarter Ended 31 December 2015
9-Feb-2016
Appendix 4C - Quarter Ended 30 September 2015
9-Feb-2016
Appendix 4G - Corporate Governance Statement
9-Feb-2016
Annual report and full year financial results - 30 June 2015
9-Feb-2016
Appendix 4C - Quarter Ended 30 June 2015
24-Dec-2015
Letter to Shareholders
9-Dec-2015
Letter to Shareholders
7-Dec-2015
Letter to Shareholders
11-Nov-2015
Letter to Shareholders /Notice of meeting of Creditors
26-Oct-2015
Letter to Shareholders
2-Oct-2015
Letter to Shareholders
15-Sep-2015
ASX Announcement
7-Sep-2015
Letter to Shareholders
24-Jun-2015
Letter to Shareholders
22-Jun-2015
ASX Announcement
27-May-2015
Response to ASX Price Query
22-May-2015
Appointment of Voluntary Administrator
22-May-2015
Suspension from Official Quotation
22-Apr-2015
Appendix 4C - Quarter Ended 31 March 2015
2-Apr-2015
Response to ASX Price Query
10-Mar-2015
Change in substantial holding
25-Feb-2015
Half Yearly Report and Accounts - 31 December 2014
27-Jan-2015
Appendix 4C - Quarter Ended 31 December 2014
29-Oct-2014
Results of 2014 Annual General Meeting
29-Oct-2014
Chairman's Address to Shareholders
24-Oct-2014
Appendix 4C - Quarter Ended 30 September 2014
26-Sep-2014
Annual Report to Shareholders - 2014
26-Sep-2014
Notice of 2014 Annual General Meeting and Proxy Form
28-Aug-2014
2014 Annual General Meeting - Wednesday, 29 October 2014
27-Aug-2014
Preliminary Final Report - 30 June 2014
14-Aug-2014
QRxPharma Halts Moxduo Development
31-Jul-2014
QRxPharma General Shareholder Update
17-Jul-2014
Appendix 4C - Quarter Ended 30 June 2014
14-Jul-2014
Initial Director's Interest Notice - Richard Treagus
14-Jul-2014
Initial Director's Interest Notice - Bruce Hancox
14-Jul-2014
Final Director's Interest Notice - Peter Campbell
14-Jul-2014
Final Director's Interest Notice - Michael Quinn
14-Jul-2014
Final Director's Interest Notice - Gary Pace
14-Jul-2014
Final Director's Interest Notice - Peter Farrell
11-Jul-2014
Feedback on End-of-Review Meeting with the FDA on Moxduo
9-Jul-2014
Results of 9 July 2014 General Meeting
9-Jul-2014
Board Resignations and General Meeting Chairman's Address
27-Jun-2014
Letter to Shareholders from Chairman of General Meeting
26-Jun-2014
Change of Director's Interest Notice - Michael Quinn
4-Jun-2014
FDA Confirms Review Meeting Regarding MOXDUO NDA
3-Jun-2014
Notice of General Meeting/Proxy Form - 9 July 2014
29-May-2014
Change of Director's Interest Notice - Peter Campbell
29-May-2014
Change of Director's Interest Notice - Michael Quinn
29-May-2014
Change of Director's Interest Notice - Peter Farrell
26-May-2014
Complete Response Letter from FDA regarding Moxduo NDA
19-May-2014
Moxduo Status Overview May 2014
14-May-2014
Notice under Sections 249D & 203D of the Corporations Act
7-May-2014
Final Director's Interest Notice - John Holaday
7-May-2014
Change of Director's Interest Notice - Gary Pace
7-May-2014
Change of Director's Interest Notice - John Holaday
2-May-2014
Appendix 3B - Option Issue
2-May-2014
CEO Remuneration Package and Key Terms
2-May-2014
Reissue - Dr. Edward Rudnic Appointed CEO of QRxPharma
2-May-2014
Dr. Edward Rudnic Appointed CEO of QRxPharma
29-Apr-2014
Appendix 4C - Quarter Ended 31 March 2014
23-Apr-2014
CEO Discusses Moxduo Advisory Committee Meeting Outcomee
23-Apr-2014
QRxPharma Issues Statement On Moxduo Advisory Committee
22-Apr-2014
FDA Webcast Details For Moxduo Advisory Committee Meeting
17-Apr-2014
Moxduo Post Advisory Committee Meeting Investor Call Details
17-Apr-2014
Trading Halt
24-Mar-2014
FDA sets 22 April 2014 for Moxduo Advisory Committee Meeting
10-Mar-2014
Appendix 3B - Exercise of Stock Options
25-Feb-2014
ASX / Media Release - Results Half Year 31 December 2013
25-Feb-2014
Half Yearly Report and Accounts - 31 December 2013
30-Jan-2014
Appendix 3B - Exercise of Stock Options
29-Jan-2014
Appendix 4C - Quarter Ended 31 December 2013
22-Jan-2014
Details of Company Address
17-Dec-2013
Holaday - Cease to be substantial holder
17-Dec-2013
Change of Director's Interest Notice - Peter Campbell
16-Dec-2013
QRxPharma Despatches SPP Holding Statements
13-Dec-2013
Appendix 3B - Share Purchase Plan
13-Dec-2013
$4.1 Million SPP Completes A$11.6 Million Capital Raising
11-Dec-2013
25 May 2014 as New PDUFA Date for MOXDUO NDA
27-Nov-2013
MOXDUO License with TEVA for Commercialisation in Israel
26-Nov-2013
QRxPharma Refiles MOXDUO New Drug Application with the FDA
19-Nov-2013
Change in substantial holding
19-Nov-2013
Appendix 3B - Option Issue
18-Nov-2013
Notification Section 708A(5)(e) Corporations Act 2001 (Cth)
18-Nov-2013
Appendix 3B - Placement Issue announced 13 November 2013
15-Nov-2013
Share Purchase Plan Opens 19 November 2013
13-Nov-2013
Placement and SPP - ASX Listing Rule 3.10.3 Notice
13-Nov-2013
Results of 2013 Annual General Meeting
13-Nov-2013
Chairman and Managing Director Addresses to Shareholders
13-Nov-2013
Successful Completion of A$7.5 Million Placement
11-Nov-2013
Investor Update and Capital Raising - November 2013
11-Nov-2013
Trading Halt
28-Oct-2013
Appendix 4C - Quarter Ended 30 September 2013
15-Oct-2013
QRxPharma Extends MOXDUO License with Aspen
10-Oct-2013
Notice of 2013 Annual General Meeting and Proxy Form
9-Oct-2013
QRxPharma reports Positive Meeting with the FDA on MOXDUO
25-Sep-2013
Annual Report to Shareholders - 2013
17-Sep-2013
2013 Annual General Meeting - Wednesday, 13 November 2013
11-Sep-2013
QRxPharma Announces MOXDUO License with Aspen
6-Sep-2013
FDA Schedules Review Meeting Regarding MOXDUO NDA
29-Aug-2013
ASX/ Media Release - Preliminary Final Report 30 June 2013
29-Aug-2013
Preliminary Final Report - 30 June 2013
28-Aug-2013
CEO discusses Complete Response Letter on Open Briefing
28-Aug-2013
Complete Response Letter from FDA regarding MOXDUO NDA
26-Aug-2013
Trading Halt
26-Jul-2013
Appendix 4C - Quarter Ended 30 June 2013
22-Jul-2013
QRxPharma Announces Collaboration with Aesica
9-Jul-2013
Change in substantial holding
27-Jun-2013
CEO discusses MOXDUO NDA Review Update on Open Briefing
26-Jun-2013
QRxPharma Updates MOXDUO NDA Review
26-Jun-2013
Trading Halt
14-Jun-2013
Appendix 3B - Exercise of Stock Options
12-Jun-2013
QRxPharma Granted US Patent on Hybrid Opioids
5-Jun-2013
Appendix 3B - Exercise of Stock Options
17-May-2013
FDA sets 17 July 2013 for MOXDUO Advisory Committee Meeting
9-May-2013
Appendix 3B - Exercise of Stock Options
29-Apr-2013
Appendix 4C - Quarter Ended 31 March 2013
14-Mar-2013
FDA sets 26 August 2013 as new PDUFA date for MOXDUO NDA
1-Mar-2013
Investor Presentation Update - March 2013
28-Feb-2013
QRxPharma Resubmits MOXDUO New Drug Application to the FDA
21-Feb-2013
Appendix 3B - Option Issue
18-Feb-2013
Investor Presentation Update - February 2013
18-Feb-2013
Half Yearly Report and Accounts - 31 December 2012
24-Jan-2013
Appendix 4C - Quarter Ended 31 December 2012
17-Jan-2013
CEO discusses Path Forward for Resubmission of MOXDUO NDA
16-Jan-2013
Path Forward For Resubmission of MOXDUO NDA
14-Jan-2013
Appendix 3B - Exercise of Stock Options
20-Dec-2012
Appendix 3B - Exercise of Stock Options
11-Dec-2012
Investor Presentation Update - December 2012
6-Dec-2012
Change in substantial holding
6-Dec-2012
MAP Cancellation
6-Dec-2012
Change in substantial holding
28-Nov-2012
Ceasing to be a substantial holder
22-Nov-2012
Change of Director's Interest Notice - Michael Quinn
22-Nov-2012
Change of Director's Interest Notice - Gary Pace
22-Nov-2012
Change of Director's Interest Notice - Peter Farrell
21-Nov-2012
Change of Director's Interest Notice - Michael Quinn
12-Nov-2012
Change of Director's Interest Notice - John Holaday
12-Nov-2012
Appendix 3B - Option Issue
12-Nov-2012
Change of Director's Interest Notice - Peter Campbell
12-Nov-2012
Change of Director's Interest Notice - Peter Farrell
12-Nov-2012
Change of Director's Interest Notice - Michael Quinn
12-Nov-2012
Change of Director's Interest Notice - Gary Pace
7-Nov-2012
Results of 2012 Annual General Meeting
7-Nov-2012
Chairman and Managing Director Addresses to Shareholders
26-Oct-2012
Appendix 4C - Quarter Ended 30 September 2012
10-Oct-2012
Strategic Collaboration with Paladin Labs
5-Oct-2012
Notice of 2012 Annual General Meeting and Proxy Form
24-Sep-2012
Change in substantial holding
21-Sep-2012
Annual Report to Shareholders - 2012
13-Sep-2012
2012 Annual General Meeting - Wednesday, 7 November 2012
6-Sep-2012
Investor Presentation Update - September 2012
3-Sep-2012
Independent Audit Report - 30 June 2012
30-Aug-2012
ASX/ Media Release - Preliminary Final Report 30 June 2012
30-Aug-2012
Preliminary Final Report - 30 June 2012
21-Aug-2012
CEO discusses Productive Meeting with FDA regarding MOXDUO
20-Aug-2012
Productive Meeting With FDA Regarding MOXDUO NDA
24-Jul-2012
Appendix 4C - Quarter Ended 30 June 2012
11-Jul-2012
Change in substantial holding
29-Jun-2012
Ceasing to be a substantial holder from BTT
29-Jun-2012
Ceasing to be a substantial holder from WBC
27-Jun-2012
CEO discusses Complete Response Letter from FDA
27-Jun-2012
Complete Response Letter from FDA regarding MOXDUO NDA
25-Jun-2012
Trading Halt
4-Jun-2012
Ceasing to be a substantial holder
23-May-2012
QRxPharma Granted Additional US Patent on MoxDuo
21-May-2012
Appendix 3B - Exercise of Stock Options
26-Apr-2012
US Commercialisation Partner Actavis to be acquired byWatson
17-Apr-2012
Appendix 3B - Exercise of Stock Options
17-Apr-2012
Appendix 3B - Option Issue
16-Apr-2012
Appendix 4C - Quarter Ended 31 March 2012
11-Apr-2012
Successful Completion of Phase 1 Studies for MoxDuo CR
27-Mar-2012
Appendix 3B - Exercise of Stock Options
19-Mar-2012
QRxPharma Signs License and Option Agreement with Actavis
6-Mar-2012
Investor Presentation Update - March 2012
2-Mar-2012
QRxPharma Presents at Cowen Health Care Live Audio Webcast
1-Mar-2012
Appendix 3B - Exercise of Stock Options
24-Feb-2012
Half Yearly Report and Accounts - 31 December 2011
14-Feb-2012
Dr. Edward Rudnic Joins QRxPharma as Chief Operating Officer
7-Feb-2012
Appendix 3B - Exercise of Stock Options
30-Jan-2012
Appendix 4C - Quarter Ended 31 December 2011
27-Jan-2012
Appendix 3B - Option Issue
27-Jan-2012
Appendix 3B - Exercise of Stock Options
23-Jan-2012
Change in substantial holding
23-Jan-2012
Change in substantial holding
23-Jan-2012
Change in substantial holding
23-Jan-2012
Change in substantial holding
10-Jan-2012
Investor Presentation Update - January 2012
30-Dec-2011
Change of Director's Interest Notice - John Holaday
28-Dec-2011
Change in substantial holding from BTT
28-Dec-2011
Change of Interest from WBC
22-Dec-2011
Appendix 3B - Exercise of Stock Options
21-Dec-2011
QRxPharma CEO discusses Strategic Partnership with Actavis
21-Dec-2011
QRxPharma Announces Strategic Partnership with Actavis
20-Dec-2011
Trading Halt Request
20-Dec-2011
Trading Halt
29-Nov-2011
Change in substantial holding x 4
22-Nov-2011
Change of Director's Interest Notice - John Holaday
18-Nov-2011
Appendix 3B - Option Issue
16-Nov-2011
Results of 2011 Annual General Meeting
16-Nov-2011
Chairman's and Managing Director's Addresses to Shareholders
8-Nov-2011
PDUFA Target Date for FDA Action on MoxDuo IR NDA Granted
4-Nov-2011
Appendix 3B - Exercise of Stock Options
27-Oct-2011
Appendix 4C - Quarter Ended 30 September 2011
17-Oct-2011
Appendix 3B - Option Issue
14-Oct-2011
2011 Notice of Annual General Meeting and Proxy Form
28-Sep-2011
Appendix 3B - Exercise of Stock Options
27-Sep-2011
Annual Report to Shareholders - 2011
20-Sep-2011
Change in substantial holding
7-Sep-2011
Becoming a substantial holder
1-Sep-2011
Change of Director's Interest Notice - Peter Farrell
1-Sep-2011
Change of Director's Interest Notice - Gary Pace
1-Sep-2011
Change of Director's Interest Notice - Michael Quinn
1-Sep-2011
Change of Director's Interest Notice - Peter Campbell
30-Aug-2011
Appendix 3B - Rights Issue
30-Aug-2011
Non-renounceable Rights Issue Despatch of Holding Statements
25-Aug-2011
QRxPharma Completes NDA Submission for MoxDuo IR
25-Aug-2011
Non-renounceable Rights Issue Notice of under subscriptions
18-Aug-2011
ASX/ Media Release - Preliminary Final Report 30 June 2011
18-Aug-2011
Preliminary Final Report - 30 June 2011
15-Aug-2011
Corporate Update and Rights Issue closing 22 August 2011
12-Aug-2011
Change of Director's Interest Notice - Michael Quinn
10-Aug-2011
Correction Web Address - CEO discussion on Boardroom Radio
10-Aug-2011
CEO on Recent Milestones and Rights Issue - Boardroom Radio
8-Aug-2011
Notice of Despatch of Rights Issue Documents to Shareholders
8-Aug-2011
Rights Issue - Notice to Ineligible Shareholders
8-Aug-2011
Rights Issue - Letter to U.S. Eligible Shareholders
2-Aug-2011
Appendix 3B - Exercise of Stock Options
28-Jul-2011
Appendix 4C - Quarter Ended 30 June 2011
27-Jul-2011
Notification Section 708A(5)(e) Corporations Act
22-Jul-2011
QRxPharma Rights Issue - Entitlement and Acceptance Form
22-Jul-2011
Non-Renounceable Rights Issue - Letter to Shareholders
22-Jul-2011
Non-Renounceable Rights Issue - Letter to Option Holders
22-Jul-2011
QRxPharma Rights Issue Booklet
22-Jul-2011
Notification Section 708AA(2)(f) Corporations Act
22-Jul-2011
Appendix 3B - Placement and Rights Issue
22-Jul-2011
QRxPharma Announces A$35 Million Capital Raising
20-Jul-2011
Investor Update and Capital Raising - 20 July 2011
20-Jul-2011
Trading Halt
18-Jul-2011
QRxPharma Announces NDA Filing for MoxDuo IR
13-Jul-2011
Appendix 3B - Option Issue
29-Jun-2011
Additional Data on MoxDuo IR Comparative Safety Study
20-Jun-2011
Investor Presentation Update - June 2011
15-Jun-2011
CEO discusses Comparative Safety Study on Boardroom Radio
14-Jun-2011
Successful Completion MoxDuo IR Comparative Safety Study
17-May-2011
Presentation of Clinical Data on MoxDuoTrials at APS Meeting
13-May-2011
Appendix 3B - Exercise of Stock Options
28-Apr-2011
Appendix 4C - Quarterly Report 31 March 2011
27-Apr-2011
Enrolment of MoxDuo IR Comparative Safety Study Completed
14-Apr-2011
USPTO Issues QRxPharma a New Patent for MoxDuo IR
8-Apr-2011
Change in substantial holding
7-Apr-2011
Change in substantial holding
28-Mar-2011
QRxPharma on Track to File New Drug Application Mid-Year
16-Mar-2011
Ceasing to be a substantial holder
21-Feb-2011
Half Yearly Report and Accounts -31 December 2010
21-Feb-2011
Investor Presentation Update - February 2011
21-Feb-2011
Successful Completion Third Pivotal MoxDuo IR Phase 3
27-Jan-2011
Appendix 4C - 31 December 2010
24-Jan-2011
Initiation of Phase 3 Comparative Safety Study of MoxDuo IR
6-Jan-2011
Appendix 3B - Option Issue
31-Dec-2010
QRxPharma Securities Trading Policy
6-Dec-2010
Enrolment of Pivotal MoxDuo IR Phase 3 Study Completed
26-Nov-2010
Change of Director's Interest Notice - Peter Campbell
26-Nov-2010
Change of Director's Interest Notice - Michael Quinn
19-Nov-2010
Appendix 3B - Share Purchase Plan
19-Nov-2010
$5.8 million SPP completes capital raising of $19.8 million
15-Nov-2010
Change of Director's Interest Notice - Michael Quinn
15-Nov-2010
Change of Director's Interest Notice - Gary Pace
15-Nov-2010
Change of Director's Interest Notice - Peter Campbell
15-Nov-2010
Change of Director's Interest Notice - John Holaday
15-Nov-2010
Change of Director's Interest Notice - Peter Farrell
12-Nov-2010
Change in substantial holding
9-Nov-2010
Appendix 3B - Option Issue
9-Nov-2010
Notification Section 708A(5)(e) Corporations Act 2001 (Cth)
9-Nov-2010
Appendix 3B - 2nd Tranche of Placement Issue
8-Nov-2010
Amended Company Constitution 8 November 2010
8-Nov-2010
Results of 2010 Annual General Meeting
8-Nov-2010
Chairman's and Managing Directors' Addresses to Shareholders
8-Nov-2010
Additional U.S.Therapeutic Discovery Project Grant Awarded
4-Nov-2010
Appendix 3B - Exercise of Stock Options
4-Nov-2010
MoxDuo Awarded U.S. Therapeutic Discovery Project Grants
27-Oct-2010
Appendix 3B - Option Issue
27-Oct-2010
Appendix 4C -30 September 2010
15-Oct-2010
Becoming a substantial holder
15-Oct-2010
Share Purchase Plan_Opens 18 October 2010
8-Oct-2010
2010 Annual Report to Shareholders - Printed and Web Copy
8-Oct-2010
Notice of Annual General Meeting/Proxy Form
7-Oct-2010
Notification Section 708A(5)(e) Corporations Act 2001 (Cth)
7-Oct-2010
Appendix 3B - Placement Issue announced 1 October 2010
6-Oct-2010
Appendix 3B - Option Issue
1-Oct-2010
Placement and Share Purchase Plan Listing Rule 3.10.3 Notice
1-Oct-2010
A$14 Million Placement together with a Share Purchase Plan
29-Sep-2010
Investor Update and Capital Raising - 29 September 2010
29-Sep-2010
Annual Report to shareholders - 2010
29-Sep-2010
Trading Halt
21-Sep-2010
Appendix 3B - Option Issue
1-Sep-2010
Interim Analysis of Final Pivotal Phase 3 Study MoxDuoIR
26-Aug-2010
ASX/ Media Release - Preliminary Final Report 30 June 2010
26-Aug-2010
Preliminary Final Report - 30 June 2010
18-Aug-2010
MoxDuo IR recognised for innovation in pain therapy
9-Aug-2010
Positive Phase 2 Proof of Concept Data for MoxDuoIV
26-Jul-2010
Investor Presentation Update July 2010
26-Jul-2010
Positive Scientific Advice Meetings in Europe MoxDou IR
26-Jul-2010
Appendix 4C - 30 June 2010
7-Jul-2010
Appendix 3B - Option Issue
21-Jun-2010
Appendix 3B- - Exercise of Stock Options
3-Jun-2010
Appendix 3B - Exercise of Stock Options
28-May-2010
Ceasing to be a substantial holder
10-May-2010
Phase 1 PK Study for MoxDuoCR Tablet Formula Successful
6-May-2010
Response to ASX Query - Appendix 4C
4-May-2010
Investor Presentation Update May 2010
4-May-2010
Phase 3 Combination Rule Study for MoxDuo IR Additional Data
27-Apr-2010
Appendix 4C - Quarterly Report 31 March 2010
23-Apr-2010
Appendix 3B - Exercise of Stock Options
14-Apr-2010
Phase 3 Combination Rule Study for MoxDuoIR Successful
9-Apr-2010
Becoming a substantial holder
9-Apr-2010
Ceasing to be a substantial holder
1-Apr-2010
Appendix 3B - Exercise of Stock Options
1-Apr-2010
Appendix 3B - Option Issue
30-Mar-2010
Phase 1 Trial of Controlled-Release Dual-Opioid Initiated
18-Mar-2010
Appendix 3B - Exercise of Stock Options
10-Mar-2010
Change in substantial holding
25-Feb-2010
Appendix 3B - Exercise of Stock Options
23-Feb-2010
Strategic Alliance for Development of MoxDuo IV
22-Feb-2010
Appendix 3B - Option Issue
17-Feb-2010
Half Yearly Report and Accounts - 31 December 2009
10-Feb-2010
QRxPharma Initiates Second Pivotal Phase 3 Study MoxDuoIR
27-Jan-2010
Appendix 4C - Quarterly Report 31 December 2009
18-Jan-2010
Change in substantial holding - John Holaday
18-Jan-2010
Becoming a substantial holder - John Holaday
11-Jan-2010
Appendix 3B - Option Issue
6-Jan-2010
Becoming a substantial holder
30-Dec-2009
Change in substantial holding from BTT
30-Dec-2009
Change in substantial holding from WBC
23-Dec-2009
Change of Director's Interest Notice - Gary Pace
23-Dec-2009
Change of Director's Interest Notice - John Holaday
23-Dec-2009
Change of Director's Interest Notice - Michael Quinn
23-Dec-2009
Change of Director's Interest Notice - Peter Farrell
23-Dec-2009
Change of Director's Interest Notice - Peter Campbell
23-Dec-2009
Appendix 3B - Rights Issue
23-Dec-2009
Change in substantial holding
21-Dec-2009
Rights Issue - Notice of Despatch of Shareholder Statements
18-Dec-2009
Appendix 3B - Rights Issue
18-Dec-2009
Notice of Subscriptions under Rights Issue
18-Dec-2009
Change of Director's Interest Notice - Michael Quinn
11-Dec-2009
Change of Director's Interest Notice - Michael Quinn
10-Dec-2009
Change of Director's Interest Notice - Gary Pace
10-Dec-2009
Change of Director's Interest Notice - John Holaday
10-Dec-2009
Corporate Update and Rights Issue closing 15 December 2009
30-Nov-2009
QRxPharma Initiates Pivotal Phase 3 Study of MoxDuoIR
30-Nov-2009
Notice of Despatch of Rights Issue Documents to Shareholders
30-Nov-2009
Rights Issue - Notice to Ineligible Shareholders
30-Nov-2009
Rights Issue - Letter to U.S. Eligible Shareholders
23-Nov-2009
Change of Director's Interest Notice - John Holaday
23-Nov-2009
Appendix 3B - Option Issue
20-Nov-2009
Becoming a substantial holder
19-Nov-2009
Appendix 3B - Placement Issue announced on 16 November 2009
16-Nov-2009
Results of 2009 Annual General Meeting
16-Nov-2009
Chairman's and Managing Directors' Addresses to Shareholders
16-Nov-2009
Reinstatement to Official Quotation
16-Nov-2009
Renounceable Rights Issue - Letter to Shareholders
16-Nov-2009
Renounceable Rights Issue - Letter to Option holders
16-Nov-2009
Appendix 3B - Placement and Rights Issue
16-Nov-2009
Notification Section 708AA(2)(f) Corporations Act 2001 (Cth)
16-Nov-2009
Renounceable Rights Issue - Entitlement and Acceptance Form
16-Nov-2009
QRxPharma Renounceable Rights Issue Booklet
16-Nov-2009
A$21.6 Million Fully Underwritten Placement and Rights Issue
13-Nov-2009
Investor Update and Capital Raising 13 November 2009
13-Nov-2009
Suspension from Official Quotation
11-Nov-2009
QRxPharma Investor Update and Capital Raising
11-Nov-2009
Trading Halt
26-Oct-2009
Appendix 4C - Quarterly Report 30 September 2009
20-Oct-2009
Completion of Strategic Alliance Deal for Venomics Assets
12-Oct-2009
Deal inked with Patheon for the Manufacture of MoxDou CR
12-Oct-2009
Notice of Annual General Meeting/Proxy Form
6-Oct-2009
Appendix 3B - Option Issue
29-Sep-2009
Ceasing to be a substantial holder
28-Sep-2009
Annual Report to Shareholders - 2009
28-Sep-2009
Change in substantial holding
25-Sep-2009
Change in substantial holding
24-Sep-2009
Strategic Alliance for the Development of Venomics Assets
31-Aug-2009
Appendix 3B - Option Issues
26-Aug-2009
Corporate Presentation Update August 2009
25-Aug-2009
MoxDuoIR Demonstrates Fewer Side Effects than Percocet
21-Aug-2009
ASX/ Media Release - Preliminary Final Report 30 June 2009
21-Aug-2009
Preliminary Final Report - 30 June 2009
29-Jul-2009
Response to ASX Query - Change of Director's Interest
28-Jul-2009
Appendix 4C - Quarterly Report 30 June 2009
23-Jul-2009
QRxPharma Initiates Comparative Phase 2 Sudy for MoxDuo IV
20-Jul-2009
Change of Director's Interest Notice - Michael Quinn
25-May-2009
Appendix 3B - Release of Shares from ASX Restriction
11-May-2009
Release of Shares from Voluntary Escrow and ASX Restriction
29-Apr-2009
Corporate Presentation Update April 2009
27-Apr-2009
Appendix 4C - Quarterly Report 31 March 2009
20-Apr-2009
Successful Completion of Comparative Study for MoxDuoIR
9-Mar-2009
Appendix 3B - Option Issues
9-Mar-2009
Change of Director's Interest Notice - Peter Farrell
23-Feb-2009
Half Yearly Report and Accounts 31 December 2008
19-Feb-2009
QRxPharma Initiates Second Comparative Study for MoxDuo IR
29-Jan-2009
Change in substantial holding
28-Jan-2009
Appendix 4C - Quarterly Report December 2008
22-Jan-2009
Dr Jesus Soriano as Executive Vice President
16-Dec-2008
QRxPharma Initiates Comparative Study for MoxDuoIR
10-Dec-2008
Change in substantial holding
9-Dec-2008
Becoming a substantial holder
4-Nov-2008
Chairman's and CEO's Address to Shareholders
4-Nov-2008
Results of 2008 Annual General Meeting
24-Oct-2008
Appendix 4C - Quarter Ended 30 September 2008
26-Sep-2008
Annual Report to Shareholders - 2008
26-Sep-2008
Notice of Annual General Meeting/Proxy Form
21-Aug-2008
ASX/ Media Release - Preliminary Final Report 30 June 2008
21-Aug-2008
Preliminary Final Report - 30 June 2008
12-Aug-2008
Change of Director's Interest Notice - Peter Farrell
5-Aug-2008
FDA Accepts Streamlined Phase 3 Development Plan Q8003IR
30-Jul-2008
Appendix 4C - 30 June 2008
3-Jul-2008
Change of Director's Interest Notice - Michael Quinn
1-Jul-2008
QRxPharma Begins Trading on the International OTCQX
1-Jul-2008
Change of Director's Interest Notice - Peter Campbell
30-Jun-2008
Change of Director's Interest Notice - John Holaday
27-Jun-2008
Change of Director's Interest Notice - Peter Farrell
3-Jun-2008
QRxPharma Corporate Presentation - June 2008
3-Jun-2008
QRxPharma Launches ADR Program
22-May-2008
Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
19-May-2008
Appendix 3B - Release of Shares from Restriction and Escrow
5-May-2008
Initial Phase 3 Study Results Dual Opioid Pain Therapy
5-May-2008
Corporate Presentation Update May 2008
28-Apr-2008
Appendix 4C - quarterly
1-Apr-2008
Appendix 3B - Option Issues
26-Feb-2008
Half Yearly Report and Accounts
15-Feb-2008
Company Secretary Appointment/Resignation
29-Jan-2008
Appendix 4C - Quarterly 31 December 2007
7-Jan-2008
QRxPharma Reports Feedback from the FDA - Q8003IR
4-Jan-2008
Change of Director's Interest Notice - Gary Pace
28-Dec-2007
Change of Director's Interest Notice - Gary Pace
20-Dec-2007
Ceasing to be a substantial holder
13-Dec-2007
QRxPharma Initiates Second Phase III Clinical Trial
6-Dec-2007
Change of Director's Interest Notice - Micahel Quinn
6-Dec-2007
Change of Director's Interest Notice - Michael Quinn
30-Nov-2007
Change of Director's Interest Notice - Peter Farrell
30-Nov-2007
Details of Company Address
30-Nov-2007
Quotation of Securities
26-Nov-2007
QRxPharma Enrolls First Patients in Phase III Clinical Trial
15-Nov-2007
Change of Director's Interest Notice - John Holaday
2-Nov-2007
Results of Meeting
2-Nov-2007
Chairman's Address to Shareholders
29-Oct-2007
QRxPharma Limited - Investor Update October 2007
25-Oct-2007
Change in substantial holding from WBC
22-Oct-2007
Appendix 4C - quarterly
27-Sep-2007
Annual Report to shareholders
27-Sep-2007
Notice of Annual General Meeting/Proxy Form
15-Aug-2007
Company Presentation Preliminary Final Report
15-Aug-2007
ASX/ Media Release - Preliminary Final Report
15-Aug-2007
Preliminary Final Report
7-Aug-2007
Becoming a substantial holder from WBC
3-Aug-2007
Ceasing to be a substantial holder from WBC
2-Aug-2007
Initial Substantial Shareholder Notice from WBC
27-Jul-2007
Appendix 4C - quarterly
19-Jun-2007
Release of Shares from Escrow
14-Jun-2007
Change of Director's Interest Notice
12-Jun-2007
Becoming a substantial holder
31-May-2007
Change of Director's Interest Notice
31-May-2007
Change of Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
25-May-2007
QRxPharma Limited completes IPO/Trading commences on ASX
25-May-2007
Pre-Quotation Disclosure
25-May-2007
Top 20 shareholders
25-May-2007
Distribution Schedule
25-May-2007
Admission to Official List
24-May-2007
ASX Circular: Commencement of Official Quotation
24-May-2007
Constitution
24-May-2007
Pre-quotation Disclosure re Shares and Options
24-May-2007
Financial Statements 31 December 2006
24-May-2007
Financial Statements 30 June 2006
24-May-2007
Financial Statements 30 June 2005
24-May-2007
Financial Statements 30 June 2004
23-May-2007
Corporate Governance Statement
23-May-2007
Full terms & conditions of ESOP
21-May-2007
Appendix 1A: ASX Listing application and agreement
16-May-2007
Disclosure Document